Rahsaan Thompson, Chief Legal & Compliance Officer at Zevra Therapeutics, Inc., filed a Form 4 on August 17, 2026, disclosing the sale of 42,666 shares of common stock on August 14, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 42,666 shares of Zevra Therapeutics common stock were disposed of on August 14, 2026.
  • Weighted average price: The weighted average sale price was $11.1277 per share, with individual trades ranging from $10.86 to $11.36.
  • 10b5-1 plan: The transaction was executed under a Rule 10b5-1(c) plan adopted on May 15, 2026.
  • Remaining ownership: Following the transaction, Thompson directly beneficially owned 37,569 shares of common stock.
  • Reporting person role: Thompson serves as Chief Legal & Compliance Officer of Zevra Therapeutics, Inc.

Zevra Therapeutics CLO Share Sale Details and 10b5-1 Plan Context

According to the filing, Rahsaan Thompson, identified as Chief Legal & Compliance Officer of Zevra Therapeutics, Inc. (NASDAQ:ZVRA), disposed of 42,666 shares of common stock on August 14, 2026. The transaction carried a transaction code of "S," indicating a sale. The filing discloses that the sale was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), with the plan adoption date listed as May 15, 2026.

The filing notes that the transaction was executed in multiple trades at prices ranging from $10.86 to $11.36 per share. The price reported, $11.1277, reflects the weighted average sale price across those trades. According to the filing, Thompson "undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."

Following the reported transaction, the filing indicates Thompson directly and beneficially owned 37,569 shares of Zevra Therapeutics common stock. No derivative securities transactions were reported in Table II. The Form 4 was signed by Timothy J. Sangiovanni as Attorney-in-Fact for Rahsaan W. Thompson and filed on August 17, 2026.

What Was Disclosed

The filing discloses a single open-market sale of 42,666 common shares by Zevra Therapeutics' Chief Legal & Compliance Officer on August 14, 2026, at a weighted average price of $11.1277, conducted under a pre-established 10b5-1 plan, leaving Thompson with 37,569 shares.